AZN AstraZeneca Earnings April 29: Q1 2026 Results

AstraZeneca PLC (AZN) reported first-quarter earnings on April 29, 2026. The pharmaceutical giant faces a critical moment as investors assess its financial health and pipeline strength. With a $317.51 billion market cap and $200.72 stock price, AstraZeneca remains a major player in global healthcare. However, specific earnings figures for Q1 2026 remain unavailable at this time. The company’s recent performance shows mixed signals. Previous quarters demonstrated both beats and misses. Meyka AI rates AZN with a B+ grade, suggesting solid fundamentals despite near-term volatility. Understanding these results matters for long-term investors tracking pharmaceutical sector trends.

AstraZeneca Q1 2026 Earnings Results Overview

AstraZeneca reported earnings on April 29, 2026, with detailed financial metrics still being processed. The company’s recent track record shows inconsistent performance across consecutive quarters.

Recent Quarter Performance Trends

Looking back at the last three quarters, AstraZeneca demonstrated variable results. In Q4 2025, the company beat EPS estimates with $1.06 actual versus $2.18 estimated, though this represented a significant miss. Revenue came in at $15.5 billion against $14.6 billion estimated, showing strong top-line performance. Q3 2025 saw EPS match estimates exactly at $1.09, while revenue missed at $14.46 billion versus $14.76 billion expected. Q2 2025 delivered an EPS beat with $1.24 actual versus $1.10 estimated, though revenue fell short at $13.59 billion against $14.06 billion projected.

Stock Price Movement and Market Reaction

AstraZeneca’s stock traded at $200.72 on April 20, 2026, down $4.08 or 1.99% from the previous close. The 52-week range spans from $132.32 to $212.71, indicating significant volatility. Year-to-date performance shows a 14.37% gain, while the one-year return stands at 51.62%. Trading volume reached 1.01 million shares, below the average of 2.28 million, suggesting cautious investor positioning ahead of earnings.

Financial Metrics and Valuation Analysis

AstraZeneca’s financial position reflects a mature pharmaceutical company with strong cash generation but elevated valuation multiples.

Profitability and Efficiency Ratios

The company maintains a 15.53 P/E ratio on trailing twelve-month earnings, reasonable for the healthcare sector. Net profit margin stands at 17.41%, demonstrating solid operational efficiency. Return on equity reaches 22.68%, indicating effective capital deployment. Operating margin of 23.40% shows strong pricing power and cost control. Free cash flow per share totals $13.64, supporting the $3.20 annual dividend with a 1.56% yield.

Balance Sheet Strength and Leverage

AstraZeneca maintains a 0.61 debt-to-equity ratio, indicating moderate leverage. Current ratio of 0.94 suggests tight working capital management. The company generated $18.92 in operating cash flow per share, providing substantial flexibility for R&D investment and shareholder returns. Interest coverage of 8.11x demonstrates comfortable debt servicing capacity. Enterprise value stands at $341.9 billion, reflecting market confidence in long-term growth prospects.

Growth Trajectory and Forward Outlook

AstraZeneca’s growth metrics reveal accelerating momentum across key financial indicators.

Revenue and Earnings Growth

Full-year 2024 revenue growth reached 13.65%, with gross profit expanding 15.24%. Operating income surged 30.85%, significantly outpacing revenue growth and indicating operational leverage. Net income grew 13.75%, while EPS increased 13.55%. Five-year revenue growth per share totals 81.39%, demonstrating consistent market expansion. Three-year net income growth per share shows exceptional 56.36% expansion, reflecting successful pipeline commercialization and cost management.

Analyst Consensus and Price Targets

Wall Street consensus shows 9 buy ratings and 2 sell ratings, with no holds. This bullish positioning reflects confidence in the company’s oncology and specialty care portfolios. Meyka AI rates AZN with a B+ grade, based on strong fundamentals, solid growth, and reasonable valuation. The rating suggests AZN remains attractive for growth-oriented healthcare investors despite near-term volatility.

Key Takeaways for Investors

AstraZeneca’s earnings performance and market position warrant careful consideration for portfolio decisions.

Strengths Supporting Long-Term Value

The company’s $317.51 billion market cap reflects its status as a global pharmaceutical leader. Strong free cash flow generation supports both R&D investment and shareholder returns. Operating margin expansion demonstrates pricing power in key therapeutic areas. Five-year revenue growth of 81.39% per share shows successful market penetration and new product launches. The B+ Meyka grade confirms solid financial health and growth prospects.

Risk Factors and Considerations

Recent quarter-to-quarter volatility in EPS and revenue suggests execution challenges or market headwinds. Patent expirations on legacy products require successful new drug commercialization. The 1.99% recent price decline reflects investor caution ahead of earnings. Valuation multiples remain elevated relative to historical averages, limiting upside if growth disappoints. Investors should monitor pipeline progress and competitive dynamics in oncology markets.

Final Thoughts

AstraZeneca reported Q1 2026 earnings on April 29, 2026, with detailed results pending full disclosure. The company’s recent performance shows mixed results, with revenue beats offset by EPS volatility across consecutive quarters. At $200.72 per share and a $317.51 billion market cap, AstraZeneca trades at reasonable multiples supported by 22.68% return on equity and 13.65% revenue growth. Meyka AI’s B+ grade reflects solid fundamentals and growth trajectory. The 9 buy ratings versus 2 sells indicate analyst confidence. Investors should focus on pipeline execution, patent cliff management, and competitive positioning in oncology. Long-term holders benefit from stro…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.